Incidence of infectious complications associated with the use of histamine2-receptor antagonists in critically III trauma patients

Annals of Surgery

Volumn 227, Issue 1, 1998, Pages 120-125

  O'Keefe, Grant E ^a   Gentilello, Larry M ^a   Maier, Ronald V ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CIMETIDINE; FAMOTIDINE; GASTROINTESTINAL MUCOSA PROTECTIVE AGENT; HISTAMINE; HISTAMINE H2 RECEPTOR ANTAGONIST; PROSTAGLANDIN; PROTON PUMP INHIBITOR; RANITIDINE; SUCRALFATE;

ANIMAL TISSUE; ARTICLE; ASPIRATION PNEUMONIA; BACTEREMIA; BACTERIAL OVERGROWTH; BONE MARROW SUPPRESSION; CATHETER INFECTION; CLINICAL TRIAL; CONTROLLED STUDY; CRITICAL ILLNESS; DRUG CONTRAINDICATION; HOSPITAL INFECTION; HUMAN; INFECTION COMPLICATION; INJURY; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMACH ACID SECRETION; STOMACH HEMORRHAGE; STRESS ULCER; URINARY TRACT INFECTION; WOUND INFECTION;

ADULT; CRITICAL ILLNESS; CROSS INFECTION; FEMALE; GASTRITIS; HISTAMINE H2 ANTAGONISTS; HUMANS; IMMUNE TOLERANCE; INCIDENCE; INFECTION CONTROL; MALE; MULTIPLE TRAUMA; PNEUMONIA; PROSPECTIVE STUDIES; RANITIDINE; RETROSPECTIVE STUDIES; RISK; SUCRALFATE;

EID: 0031891321     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000658-199801000-00017     Document Type: Article

References (16)

1. Cook DJ, Fuller HD, Guyatt GH, et al. Risk factors for gastrointestinal bleeding in critically ill patients. N Engl J Med 1994; 330(6):377-381.
2. Neugebauer E, Lorenz W, Beckurts T, et al. Significance of histamine formation and release in the development of endotoxic shock: proof of current concepts by randomized controlled studies in rats. Rev Infect Dis 1987;9(supp 5):S585-S593.
3. Hahm KB, Kim WH, Lee SI, et al. Comparison of immunomodulative effects of the histamine-2 receptor antagonists cimetidine, ranitidine and famotidine on peripheral blood mononuclear cells in gastric cancer patients. Scand J Gastroenterol 1995;30(3):265-271.
4. Rixen D, Neugebauer E, Lechleuthner A, et al. Beneficial effects of H2-agonism and H1-antagonism in rat endotoxic shock. Shock 1994;2(1):47-52.
5. Maier RV, Mitchell D, Gentilello L. Optimal therapy for stress gastritis. Ann Surg 1994;220(3):353-360.
6. Cheung LY. Pathogenesis, prophylaxis and treatment of stress gastritis. Am J Surg 1988;156:437-440.
7. Hastings PR, Skillman JJ, Bushnell LS, Silen W. Antacid titration in the prevention of acute gastrointestinal bleeding. N Engl J Med 1978;298:1041-1045.
8. Shuman RB, Schuster DP, Zuckerman GR. Prophylactic therapy for stress ulcer bleeding: a reappraisal. Ann Intern Med 1987;106:562-567.
9. Cook DJ, Reeve BK, Guyatt GH, et al. Stress ulcer prophylaxis in critically ill patients: resolving discordant meta-analyses. JAMA 1995;275(4):308-314.
10. Vincent JL, Bihari DJ, Suter PM, et al. The prevalence of nosocomial infection in intensive care units in Europe. JAMA 1995;274(8):639-644.
11. Antonelli M, Moro ML, Capelli O, et al. Risk factors for early-onset pneumonia in trauma patients. Chest 1994;105(1):224-228.
12. Rodriguez JL, Gibbons KJ, Bitzner LG, et al. Pneumonia: incidence, risk factors, and outcome in injured patients. J Trauma 1991; 31(7):907-912.
13. Cook DJ, Laine LA, Guyatt GH, Rafrin TA. Nosocomial pneumonia and the role of gastric pH: a meta-analysis. Chest 1991;100:7-13.
14. Driks MR, Craven DE, Celli BR, et al. Nosocomial pneumonia in intubated patients given sucralfate as compared with antacids or histamine type 2 blockers. N Engl J Med 1987;317(22):1376-1382.
15. Mehta J, Powles RL, Treleaven J, et al. Cimetidine-induced myelo-suppression after bone marrow transplantation. Leuk Lymphoma 1994;13(1-2):179-181.
16. Nielsen HJ, Nielsen H, Jensen S, Moesgarrd F. Ranitidine improves postoperative monocyte and neutrophil function. Arch Surg 1994;129:309-315.